Answer:
1.This doesn't help COMPLETELY get rid of pollution. It might help lessen the pollution, but it definitely won't solve it, because there are also other things that cause pollution.
2.The main problem with solar power that has stifled its use is the fact that energy production only takes place when the sun is shining. And it won't be beneficial to the countries that aren't really close to the equator ( the middle east) and that might be a problem cause there just might not be enough energy/electricity.
Answer:
Optical trapping interferometry
Explanation:
Optical trap is a device which can measure forces or dielectric objects of magnitude of Pico newton or micron.
In this, a high focused light beam is used to view objects under the microscope. It is highly used in molecular and cell biology and biophysics
This methodology has been adapted to sort lipids at cell surface and in activation of kinase in the dendritic cells
The answer is B
the earth indeed does generate heat although it wouldnt nearly be enough to hold the amount of life that prospers on earth......A is just stupid same for C so B is your answer .... :) hope it helps
Parental Phenotypes: "Yellow-Smooth", "Yellow-Wrinkled", "Green-Smooth", "Green Wrinkled".
Parental Genotypes: SsGg × SsGg
Parental Gametes: SG, Sg, sG, sg
<span>
Smooth/Green </span>= S-G- = 9
<span>
Winkled/Green </span>= ssG- = 3
Smooth/Yellow = S-gg = 3
Wrinkled/Yellow = ssgg = 1
Ratio would be: 9: 3: 3: 1
Hope this helps!
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
